Abstract: The Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in human cancers, particularly in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Historically considered "undruggable," the discovery of a cryptic switch-II pocket in the KRAS G12C mutant has led to the development of targeted covalent inhibitors. Adagrasib (MRTX849) is a potent, mutant-selective small molecule that irreversibly binds to KRAS G12C, locking it in an inactive GDP-bound state and halting downstream oncogenic signaling. While initially approved for non-small cell lung cancer (NSCLC), Adagrasib has demonstrated significant clinical activity in gastrointestinal malignancies, including CRC and PDAC. However, its efficacy as a monotherapy in CRC is limited by primary resistance driven by EGFR pathway reactivation, and acquired resistance inevitably emerges through secondary KRAS mutations and bypass signaling pathways. This review synthesizes current literature on Adagrasib, focusing on its pharmacological activity, molecular mechanism, structure-activity relationship, current limitations, and future perspectives, including promising combination therapies designed to overcome resistance in pancreatic and gastrointestinal cancers.
1. Introduction
Mutations in the KRAS oncogene are among the most prevalent drivers of human malignancies, occurring frequently in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) [7][13]. For decades, KRAS was deemed an "undruggable" target due to its exceptionally high affinity for intracellular guanosine triphosphate (GTP) and the apparent lack of deep pharmacological pockets suitable for small-molecule binding [3][13]. This paradigm shifted with the discovery of a cryptic pocket in the switch-II region of the KRAS G12C mutant, which enabled the design of direct, covalent inhibitors [1][8].
Adagrasib (MRTX849) is a highly potent, mutant-selective covalent inhibitor of KRAS G12C [1]. While the G12C mutation is predominantly found in NSCLC, it is also present in approximately 3-4% of CRC cases and 1-2% of PDAC cases [3][9][15]. Patients harboring these mutations in gastrointestinal cancers typically face aggressive disease trajectories and poor overall survival, representing a critical unmet clinical need [2][3]. The advent of Adagrasib has opened new therapeutic avenues for these specific KRAS-driven gastrointestinal and pancreatic tumors.
2. Pharmacological Activity
Adagrasib has demonstrated encouraging clinical activity across multiple KRAS G12C-mutated solid tumors. In colorectal cancer, early-phase clinical trials (such as KRYSTAL-1) evaluating Adagrasib monotherapy at the recommended dose of 600 mg twice daily reported an objective response rate (ORR) of 17% to 19% and a high disease control rate (DCR) ranging from 86% to 94% [5][12][17]. The median progression-free survival (mPFS) for CRC patients on monotherapy was approximately 4.0 to 5.6 months, with a median overall survival (mOS) reaching 19.8 months [5][17].
In pancreatic cancer (PDAC), Adagrasib monotherapy showed notable efficacy, achieving an ORR of 33.3%, an mPFS of 5.4 months, and an mOS of 8.0 months [15]. Furthermore, in biliary tract cancers, it achieved an ORR of 41.7% [15]. Pharmacokinetically, Adagrasib exhibits a long half-life of approximately 24 to 24.7 hours, which allows for sustained target inhibition and durable anti-tumor activity [5][12][14].
3. Molecular Mechanism of Action
Adagrasib functions as a covalent allosteric inhibitor that selectively targets the KRAS G12C mutant protein [12]. It irreversibly binds to the mutant cysteine residue at codon 12 within the switch-II pocket of the KRAS protein [8][14]. By occupying this pocket, Adagrasib locks the KRAS G12C protein in its inactive, GDP-bound state (the "OFF" state) [11][14].
This covalent binding prevents nucleotide exchange and the subsequent transition of KRAS to the active GTP-bound state. Consequently, Adagrasib effectively halts downstream oncogenic signaling cascades, most notably the Raf/MEK/ERK and PI3K/AKT/mTOR pathways, leading to impaired cell viability, inhibition of proliferation, and tumor regression [2][8][14].
4. Structure-Activity Relationship (SAR)
The development of Adagrasib was driven by structure-based drug design, optimizing precursor tool compounds (such as MRTX1257) to maximize efficacy, selectivity, and tolerance [5]. The binding of Adagrasib relies heavily on the specific architecture of the KRAS G12C cryptic pocket, which is formed by residues H95, Y96, and Q99 [11].
A critical feature of Adagrasib's SAR is its reliance on hydrogen-mediated bonding between the hydroxyl group of the Y96 residue and the pyrimidine ring of the Adagrasib molecule [11]. This specific interaction distinguishes it from other G12C inhibitors like sotorasib, which utilizes water bridges with a carboxyl group [11]. Because of this structural dependence, mutations affecting the Y96 codon (such as Y96D or Y96C) directly disrupt this crucial hydrogen bond, conferring strong cross-resistance to Adagrasib [2][11][16].
5. Current Limitations
Despite its clinical efficacy, Adagrasib therapy faces several significant limitations. First, the drug is associated with treatment-related adverse events, predominantly gastrointestinal toxicities (nausea, diarrhea, vomiting), fatigue, asthenia, and hepatic functional impairment (elevated ALT and AST levels) [2][6][12].
Second, primary resistance is a major hurdle in CRC. Monotherapy response rates in CRC (17-19%) are notably lower than in NSCLC (approx. 43-45%) due to rapid upstream reactivation of the EGFR signaling pathway when KRAS is inhibited downstream [3][11].
Third, acquired resistance inevitably emerges through both on-target and off-target mechanisms. On-target resistance involves secondary mutations in the switch-II pocket (e.g., Y96C, R68S, H95) or other KRAS activating mutations (e.g., G12D, G12V, G12W, Q61H) [2][16]. Off-target bypass mechanisms include MET amplification, activating mutations in NRAS, BRAF, MAP2K1, and RET, as well as oncogenic fusions involving ALK, RET, and BRAF [1][16]. Additionally, co-occurring mutations in genes such as KEAP1 or STK11 can negatively impact the therapeutic response to Adagrasib [1][6].
6. Future Perspectives
To overcome resistance and improve outcomes in gastrointestinal cancers, combination strategies are at the forefront of future research. In CRC, combining Adagrasib with the anti-EGFR antibody cetuximab has shown remarkable synergy, increasing the ORR to 43-46% and the DCR to 100%, and is currently being evaluated in the Phase III KRYSTAL-10 trial [3][15][17]. Other promising combinations include pairing Adagrasib with SHP2 inhibitors (e.g., TNO155), SOS1 inhibitors, mTOR inhibitors, and immune checkpoint inhibitors (anti-PD-1/PD-L1) [1][10][18].
Furthermore, the development of next-generation "tri-complex" inhibitors (such as RMC-6291) that target the active GTP-bound (ON) state of KRAS G12C aims to thwart RTK-mediated escape mechanisms [12]. Finally, the chemical scaffold of Adagrasib is being adapted to target other prevalent KRAS mutations, such as KRAS G12D (e.g., MRTX1133), which holds immense potential for the broader treatment of pancreatic and colorectal cancers where G12D is the dominant mutation [16][19].
